Avalyn Pharma Inc.
AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled medicines for serious rare respiratory diseases. Its current programs center on pulmonary fibrosis and other interstitial lung diseases, using formulations designed to deliver established antifibrotic medicines directly to the lungs. The company’s pipeline includes AP01 and AP02, inhaled versions of pirfenidone and nintedanib for conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, as well as AP03, a combination approach intended to provide dual antifibrotic activity. Avalyn Pharma Inc. operates in the biotechnology segment of the healthcare market and is oriented toward targeted therapies for unmet needs in rare lung disease.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (FY)
-$85M
▼ -71.3% YoY
Op. Margin
–
ROIC
-8642.38%
Cash Flow & Balance Sheet
FCF (FY)
-$82M
▼ -68.8% YoY
Op. Cash Flow (FY)
-$81M
▼ -68.5% YoY
Net Debt
-$137M
Net Cash Position
Cash & Equiv.
$138M
Continue Research
Peers
Biotechnology · Pick stocks to compare with AVLN
Held by ETFs
AVLN is in 8 US ETFs. The largest of them, with AVLN's weight in each:
iShares Russell 2000 Growth ETFIWO0.02%of the fund
T. Rowe Price Small-Mid Cap ETFTMSL0.07%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.02%of the fund
iShares U.S. Pharmaceuticals ETFIHE0.10%of the fund
State Street SPDR S&P Pharmaceuticals ETFXPH0.78%of the fund
T. Rowe Price Health Care ETFTMED0.18%of the fund
Avalyn Pharma (AVLN) in two numbers
Questions about Avalyn Pharma
Is Avalyn Pharma a high-quality business?
Avalyn Pharma scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$137M, and its weakest is return on capital at -8642.4%. The Quality tab shows every check against its target.
Does Avalyn Pharma (AVLN) pay a dividend?
No. Avalyn Pharma (AVLN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AVLN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.